CTRI/2020/10/028626已完成4 期
A Phase 4 Study of Nivolumab in Combination with Ipilimumab in Patients with Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk Factors Conducted in India - There is no Trial Acronym. The study number is CA209-7C9
BRISTOL MYERS SQUIBB INDIA PRIVATE LIMITED0 个研究点目标入组 101 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 101
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1) Signed Written Informed Consent
- •a) Participants must have signed and dated an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written ICF in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocolrelated procedures that are not part of normal participant care.
- •b) Participants must be willing and able to comply with scheduled visits, treatment schedule,laboratory tests, biomarker and PK testing, and other requirements of the study.
- •2) Type of Participant and Target Disease Characteristics
- •a) Histological confirmation of renal carcinoma with clear cell component including participants who may have sarcomatoid features. Advanced (not amenable to curative surgery or radiation therapy) RCC or mRCC.
- •b) No prior systemic therapy for RCC with the following exception:
- •i) One prior adjuvant or neoadjuvant therapy for completely resected RCC
- •2b). These drugs must be discontinued ï?³ï? 6 months prior to study entry. All AEs related to prior adjuvant or neoadjuvant therapy must have returned to baseline, and eligible patients must not have experienced severe or life-threatening immune-related AEs except those that are unlikely to reoccur with standard countermeasures (eg, hormone replacement after adrenal crisis).
- •c) Measurable disease lesion by CT or MRI per RECIST 1.1 criteria. Radiated lesions cannot be used as measurable lesions unless there is clear evidence of progression.
- •d) KPS of at least 70%
- •e) Qualifies as intermediate or poor risk by meeting least 1 of the following prognostic factors as per the IMDC criteria:
- •i) KPS less than 80
- •ii) Less than 1 year from diagnosis including original localized disease (if applicable) to study enrollment
- •iii) Hemoglobin less than the lower limit of normal
- •iv) Corrected calcium concentration greater than 10 mg/dL.
- •v) Absolute neutrophil count greater than the ULN
- •vi) Platelet count greater than the ULN
- •3) Age and Reproductive Status
- •a) Male and female participants must be 18 years or older at the time of informed consent(ICF)
- •b) Women of childbearing potential (WOCBP) must have a negative serum or urine
- •pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human horionic gonadotropin [HCG]) within 24 hours prior to the start of study treatment.
- •c) Women must not be breastfeeding.
- •d) WOCBP must agree to follow instructions for method(s) of contraception for the duration of study treatment plus 5 half-lives of study treatment plus 30 days (duration of ovulatory cycle) for a total of 5 months after the last dose of study treatment.
- •e) Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception and fetal protection (Appendix 4) for the duration of treatment with nivolumab and ipilimumab plus 7 months after the last dose of study treatment. In addition, male participants must be willing to refrain from sperm donation during this time.
- •f) WOCBP who are continuously not heterosexually active are also exempt from
- •contraceptive requirements, and still must undergo pregnancy testing as described in this section.
- •g) Azoospermic males are exempt from contraceptive requirements unless the potential exists for fetal toxicity due to study drug being present in seminal fluid, even if the part
排除标准
- 未提供
研究者
相似试验
撤回
不适用
A Phase II Study of Nivolumab in Combination with Radiation Therapy as Definitive Treatment for Patients with Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.KCT0004049Samsung Medical Center26
已完成
2 期
O LIMIT StudyJPRN-jRCT2080225304Hisato Kawakami (Coordinating Investigator)28
进行中（未招募）
1 期
An Investigational Immunotherapy Study to Determine Which Combination of Nivolumab plus Several Other Drugs, is the Most Effective in Treating Castration-resistant Prostate Cancer That Has SpreadEUCTR2017-001626-17-DEBristol-Myers Squibb International Corporation330
进行中（未招募）
1 期
An Investigational Immunotherapy Study to Determine Which Combination of Nivolumab plus Several Other Drugs, is the Most Effective in Treating Castration-resistant Prostate Cancer That Has SpreadCastration-resistant Metastatic Prostate CancerMedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-001626-17-ESBristol-Myers Squibb International Corporation300
进行中（未招募）
1 期
A Study of Nivolumab and Ipilimumab Combined with Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 9LA)Stage IV Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-001195-35-PLBristol-Myers Squibb International Corporation840